From Startup to Nasdaq: Shaun Bagai on Clinical Evidence, Physician Trust, and Scaling RenovoRx скачать в хорошем качестве

From Startup to Nasdaq: Shaun Bagai on Clinical Evidence, Physician Trust, and Scaling RenovoRx

After stepping away from the traditional path to medical school, Shaun Bagai pursued a different way to impact patient care: building technologies that change how treatments reach patients. That path eventually led him to RenovoRx, where the challenge wasn’t just developing innovative oncology technology; it was proving its value in a clinical environment that demands rigorous evidence. In this episode of Pharma Sessions, host Jonathan Kaskey sits down with Shaun Bagai, CEO of RenovoRx, to unpack the 11-year journey of scaling a two-person startup into a Nasdaq-listed company advancing Phase 3 trials. Bagai shares why physician feedback forced a complete commercial pivot, how prioritizing clinical evidence over quick exits shaped the company’s trajectory, and why real-world relationships with clinicians remain one of the most powerful advantages in healthcare commercialization. What You’ll Learn: Why saying "no" to your board's quick-flip strategy was the inflection point How to identify when physician feedback should reshape your commercial roadmap The irreplaceable competitive advantage of face-to-face field presence How to build a lean, efficient salesforce without sacrificing market intelligence The leadership paradox of staying hands-on in a small organization Why turning down med school and stable Medtronic roles paid off, and how to evaluate your own "leap" decision Shaun Bagai is CEO of Renovo RX, a NASDAQ-listed oncology company pioneering transarterial micro perfusion, a breakthrough drug delivery platform that localizes chemotherapy directly to tumors. With over two decades of experience spanning clinical research, regulatory affairs, and commercial strategy across Medtronic, Heartflow, and multiple high-impact startups, Bagot has built a reputation for translating early-stage innovation into scalable, evidence-based solutions. YouTube Chapters: [00:00] Intro [02:29] From Med School to Building Companies That Impact Patients [08:40] Why Shaun Left Stable Medtronic Roles for Two-Person Startups [14:33] The Clinical Trial Turning Point: When Physicians Demand Evidence [17:12] Building Consensus When Your Board Says "Over My Dead Body" [18:26] Hyperlocalized Drug Delivery: Targeting Tumors Without Systemic Toxicity [20:56] Why Precision Drug Delivery Is the Future of Cancer Treatment [22:31] Face-to-Face Relationships as Your Unfair Competitive Advantage [24:33] The "Invisible Weight" of CEO Communication in Small Teams [26:41] The AI World Still Can't Replicate the Elevator Conversation [28:46] Advice for Taking the Leap: Mentorship, Gut Instinct, and Alignment [30:38] Key Takeaways: Evidence Over Hype, Relationships Over Efficiency Episode Resources: RenovoRx Website: https://renovorx.com/ Shaun Bagai on LinkedIn:   / shaun-r-bagai   Jonathan Kaskey on LinkedIn:   / jonkaskey   XSUNT Corporation Website: http://www.xsunt.com/